Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

GlobeNewswire April 30, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

GlobeNewswire April 28, 2025

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 22, 2025

Medicenna to Present at Jones Healthcare and Technology Innovation Conference

GlobeNewswire April 1, 2025

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswire March 26, 2025

Medicenna Reports MDNA11's Compelling Anti-Cancer Activity is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

GlobeNewswire February 25, 2025

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

GlobeNewswire February 13, 2025

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

GlobeNewswire February 5, 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire December 13, 2024

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

GlobeNewswire December 5, 2024

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

GlobeNewswire November 27, 2024

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

GlobeNewswire November 25, 2024

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

GlobeNewswire November 15, 2024

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire November 13, 2024

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

GlobeNewswire November 11, 2024

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 8, 2024

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

GlobeNewswire October 15, 2024

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 4, 2024

Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewswire September 26, 2024

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire September 9, 2024